Extracorporeal Photopheresis in Children and Young Adults With Refractory Acute Graft Versus Host Disease
NCT00824954 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2011-01-19
Summary
Purpose : to evaluate the efficacy of ECP in children with refractory acute GVHD This study addresses patients with persistent GVHD after steroid and/or monoclonal antibody therapy
Conditions
Interventions
- PROCEDURE
-
ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis)
ECP (performed on Thermos UVAR-XTS or external UVA irradiator after cell collection by apheresis)
Sponsors & Collaborators
-
University Hospital, Clermont-Ferrand
lead OTHER
Principal Investigators
-
Etienne Merlin · University Hospital, Clermont-Ferrand
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Max Age
- 30 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-06-30
- Primary Completion
- 2012-06-30
- Completion
- 2012-12-31
Countries
- France
Study Locations
More Related Trials
-
Phase I Clinical Trial to Assess Safety of UV Phototherapy for the Prevention of GVHD Post Allogeneic SCT
NCT00524953 ·Status: WITHDRAWN ·Phase: PHASE1
-
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
NCT00054600 ·Status: COMPLETED ·Phase: PHASE2
-
Photopheresis for the Treatment of Acute Graft Versus Host Disease
NCT00609609 ·Status: COMPLETED ·Phase: PHASE2
-
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
NCT05515029 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
NCT06756152 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease
NCT01174940 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion
NCT00987987 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host Disease
NCT05515692 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Steroids Versus ECP and Steroids as First-line Treatment of Grade II Acute GVHD
NCT06133192 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention
NCT01487577 ·Status: COMPLETED ·Phase: PHASE2
-
Theralux Extracorporeal Photochemotherapy (ECP) in Patients With Extensive Chronic Graft Versus Host Disease (GvHD)
NCT00248365 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation
NCT06865352 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
NCT01012492 ·Status: COMPLETED ·Phase: PHASE2
-
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
NCT01772953 ·Status: COMPLETED ·Phase: PHASE2
-
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
NCT03779854 ·Status: RECRUITING ·Phase: PHASE2
-
Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)
NCT01380535 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia
NCT02845596 ·Status: COMPLETED ·Phase: NA
-
Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant
NCT02300571 ·Status: UNKNOWN
-
Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD
NCT00759018 ·Status: NO_LONGER_AVAILABLE
-
Allogeneic Hematopoietic Stem Cell Transplantation
NCT00750126 ·Status: UNKNOWN ·Phase: PHASE2
-
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
NCT01231412 ·Status: COMPLETED ·Phase: PHASE3
-
Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
NCT00057954 ·Status: TERMINATED ·Phase: PHASE2
-
Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease
NCT00295971 ·Status: COMPLETED ·Phase: PHASE1
-
Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
NCT02053545 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
NCT00795132 ·Status: COMPLETED ·Phase: PHASE2